Abstract: Sexual function is an important component of men's health. The prevalence of erectile dysfunction (ED) in Korea has been reported as 18-36.6% whereas Asian data showed a wide range from 2% to 88%. In 2013, the Korean Society for Sexual Medicine and Andrology (KSSMA) developed the Korean Guideline of ED. Risk factors for ED included age, diabetes, hypertension, obesity, lack of exercise, dyslipidemia, smoking, depression, lower urinary tract symptoms, and pelvic surgery. This guideline showed that lifestyle changes and modification of risk factors should be educated along with specific treatment of ED, such as pharmacological treatment. In Korea, there are many oral phosphodiesterase type 5 (PDE5) inhibitors on market such as sildenafil, vardenafil, tadalafil, udenafil, mirodenafil, avanafil, and also generic versions of sildenafil and tadalafil. The guideline showed that the choice of PDE5 inhibitors should be based on the patient's experience under a physician's guidance regarding the characteristics of each PDE5 inhibitors. The prevalence of c in Korea has been reported to be around 11.3% to 33%. Recent Korean nationwide survey showed that the main treatment modality for PE patients was selective-serotonin reuptake inhibitor (SSRI) therapy such as dapoxetine, dorsal nerve neurectomy, local anesthetics and behavior therapy. The sexual health is a crucial part of men's health. Therefore, it is needed to develop a strategy to improve sexual health for better life in Asian men. 
AB026. Relationship between post-voided dribbling and erectile dysfunction in men with lower urinary tract symptoms Abstract: The men's desire to have larger and longer penis have created endless medical demands throughout human history. Until up to date, various medical skills for penile augmentation have developed in aspect of experimental and clinical outcome. Recently with throwing away socially unacceptable ideas, the need for penile augmentation is considered as equivalent level with mammoplasty for breast augmentation in women for cosmetic and psychological reason. Concurrently advanced technologies in medical material and tissue engineering provide a variety of options to features functional plastic surgery as well as defected tissue compensation procedures. This creative description works accordingly presents state of art knowledge on the penile augmentation with more than 100 full-colored helpful illustrations clarifying penile surgical anatomy, operative procedures by experienced surgeon from the traditional fat transfer to the penile disassembly technique, the newest tissue engineering techniques by researchers with valuable data of world top level, auxiliary medical devices, and how to reconstruct for damaged penis by a quack or accident. Obviously this text book will be a great guidebook in clinical practice for all who are involved or interested in the penile augmentation procedure. Abstract: The advent of phosphodiesterase type 5 (PDE5) inhibition as oral therapy has significantly revolutionized both clinical and basic research in the area of erectile dysfunction (ED). Much of this progress is due to a better understanding in the last three decades of the various pathophysiological and cellular mechanisms contributing to ED. Apart from the three available PDE5 inhibitors viz., sildenafil, tadalafil and vardenafil globally at the turn of this century, four other PDE inhibitors have joined the armament in recent time; these include avanafil, lodenafil, mirodenafil and udenafil. All seven PDE inhibitors are effective therapies for the treatment of ED in men. There is no significant difference among them with respect to efficacy, safety profile and tolerability. As such, good safety profiles have widened the horizon in patient choice, selectivity and efficacy. With the ease of oral administration and better patient compliance, other measures of the past, including intracavernosal injections and nonpharmacological treatments have been relegated to secondline therapy for most patients with ED. But, PDE inhibitors as first-line oral therapies are effective in about 75% of male patients diagnosed with ED. Intracavernous injection (IC) 
